immune system
• reduced IL-2-activated NK cytotoxicity against tumor cell lines
• impaired binding (conjugate formation) to target cells
• normal lymphocyte development and normal numbers of leukocyte subpopulations
• normal IL-2-activated NK cell differentiation and activation
|
• serum levels of IL-10 are elevated following a low dose LPS challenge compared to similarly treated wild-type mice due to an increase in cytokine producing cells
|
• serum levels of IL-2 are elevated following a low dose LPS challenge compared to similarly treated wild-type mice due to an increase in cytokine producing cells
|
• serum levels of TNF-alpha levels are elevated following a low dose LPS challenge compared to similarly treated wild-type mice due to an increase in cytokine producing cells
|
• mice are resistant to death induced by up to 1000 times the normally lethal dose of LPS
• mice fail to exhibit liver injury in response to low doses of LPS with only marginal signs of apoptosis at 8 hours compared to wild-type mice that exhibit hepatocyte destruction at 6 hours
• TNF-alpha, IL-2 and IL-10 levels are elevated following a low dose LPS challenge compared to similarly treated wild-type mice due to an increase in cytokine producing cells
• following treatment with a lose dose of LPS, platelet levels fail to increase as much as in heterozygous mice
|
homeostasis/metabolism
• serum levels of IL-10 are elevated following a low dose LPS challenge compared to similarly treated wild-type mice due to an increase in cytokine producing cells
|
• serum levels of IL-2 are elevated following a low dose LPS challenge compared to similarly treated wild-type mice due to an increase in cytokine producing cells
|
• serum levels of TNF-alpha levels are elevated following a low dose LPS challenge compared to similarly treated wild-type mice due to an increase in cytokine producing cells
|
hematopoietic system
• following treatment with a lose dose of LPS, platelet levels fail to increase as much as in heterozygous mice
|
• reduced IL-2-activated NK cytotoxicity against tumor cell lines
• impaired binding (conjugate formation) to target cells
• normal lymphocyte development and normal numbers of leukocyte subpopulations
• normal IL-2-activated NK cell differentiation and activation
|